Guselkumab 100 mg    (DrugBank: Guselkumab)

1 disease
IDDisease name (Link within this page)Number of trials
37Generalised pustular psoriasis1

37. Generalised pustular psoriasis    [ 58 clinical trials,   50 drugs,   (DrugBank: 18 drugs),   17 drug target genes,   96 drug target pathways]
Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 58 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03998683
(ClinicalTrials.gov)
September 3, 201925/6/2019A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisPsoriasisDrug: Guselkumab 100 mg;Drug: PlaceboJanssen-Cilag Ltd.NULLActive, not recruiting18 YearsN/AAll117Phase 3France;Germany;Italy;Spain;United Kingdom